Pramesh CS Profile picture
25 Dec, 23 tweets, 5 min read
The WHO’s chief scientist on a year of loss and learning nature.com/articles/d4158…
For anyone remotely involved in healthcare, these are life lessons from @doctorsoumya. A must read.
For those of you who want a quick analysis, thread.
Disclaimer: I’m just breaking this up & annotating them with my own comments. Between quotes are her exact words (with some poetic license)
Planning ahead & prioritizing first steps – an important aspect of taking up a new job
“My original plan for 2020 included rolling out new processes to ensure the quality of technical documents, such as guidelines on water quality, tobacco advertising and immunization programmes”
The ability and sheer necessity of changing plans at short notice – a necessary skill for handling the pandemic
“All those plans changed on 31 Dec 2019. WHO was informed about a cluster of viral-pneumonia cases of unknown origin in Wuhan, China: the disease later named COVID-19”
Two crucial attributes of a leader: Believe in and credit the team; Accept your own and your organization’s weaknesses.
“I am proud of many things my team has achieved in the past 12 months, even as the shortcomings of both the WHO and the global community have been laid bare”
Face challenges head-on
“We’ve had to balance speed & rigour. We’ve had to raise alarm without causing panic. We’ve had to convince countries without openly criticizing them (which would risk losing their cooperation). We’ve had to fight the ‘infodemic’, sticking to science”
The cross leaders bear… the burden of responsibility
“Countries, especially low- and middle-income ones, depend on the WHO to decide how to combat disease and preserve public health”
Learning from past mistakes, and having the courage to acknowledge them
“In 2007, following much (largely deserved) criticism of its procedures, such as not always basing decisions on evidence, the WHO set out rigorous, standardized procedures; transparency, evidence-base & COI”
Breaking convention to handle a crisis
“A typical WHO conference requires months to plan — it takes that long for visas to come through. We pulled it off with three weeks’ notice, finding ways to involve those who couldn’t travel”
The failure of much of scientific research – small, underpowered studies
“it quickly became apparent that we needed global coordination for clinical trials — some 2,000 were already under way, most of which were too small to be definitive”
When life serves you lemons, make lemonade…
“We launched prospective meta-analyses encouraging principal investigators running trials of corticosteroids for treatment of COVID-19 to collaborate and share data”
The power of persuasion
“It contacted about a dozen researchers running clinical trials of the steroid dexamethasone, convinced them to share data even while the trials were ongoing
Normally, such guidelines take 6–12 months to produce; the committee has cut the time to 6 weeks”
The whole should be [and usually is larger (and better)] than the sum of its parts…
“This led to the WHO engaging more than 90 institutions in a new partnership; we set up advisory groups of global experts for more than 20 topics”
There is no need to monopolize the effort (and the credit); there’s plenty for us (and others) to do
“The Cochrane Collaboration has a similar initiative— there is more than enough of this work to do”
Never waste a good crisis…
“The one thing I’m proudest of is the setting up of a multi-country, adaptive clinical trial to test multiple treatments at once. This format adds or removes trialled therapeutic agents as new data emerge, while continuing to recruit participants”
The humility to accept that “the slaying of a beautiful hypothesis by an ugly fact” is what science is about
“Interim results from 12,000 participants from 30 countries have been disappointing, with none of the tested drugs showing reductions in mortality or disease progression”
Yet, look at the bright side of life.
“But the approach has shown how to perform high-quality randomized clinical trials to assess potential drugs and answer public-health questions even during a pandemic”
The dangers of disinformation & fake news – an epidemic of the modern world
“Meanwhile, the WHO has been communicating evidence and debunking misinformation as never before. Launched in March, the WHO Health Alert chatbot counters false information”
An underrated statement – why researchers should share data.
“We need a stronger infrastructure and culture of sharing.
Looking ahead, funders, institutions and other players need to create better mechanisms to reward researchers who share … data”
The importance of preparedness; and having a plan.
“As I have sought ways to make good decisions quickly, the lesson that repeats itself is how important it is to have thoughtful plans prepared and in place”
Paraphrasing @PeterASinger: Good leadership is the best vaccine
“The countries that have best protected the lives and livelihoods of their citizens have also demonstrated strong, compassionate leadership, at political and technical levels”
The real bottomline – no shortcuts to good healthcare systems and a culture of R&D.
“…have health-care systems that engage local and global communities. These qualities require long-standing investments in people and relationships, as well as in research and development”
The power (& need) for effective communication
“Not coincidentally, I have seen the value of listening & two-way communication. Scientists talk to each other, but too often leave others behind. Citizens want to know what the evidence is, including explaining gaps or mistakes” End

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Pramesh CS

Pramesh CS Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cspramesh

17 Oct
The preprints of the #SOLIDARITY trial are out on MedRxiv. While many may lament that all four drugs tested did not show benefit, this is a remarkable trial for many reasons. Thread
First, this was another #MultiArmMultiStage #MAMS study design; @MRCCTU made this highly efficient trial design globally acclaimed with #STAMPEDE. The more recent #RECOVERY trial was another example of this.
@MaxParmarMRCUCL @Prof_Nick_James @PeterHorby @MartinLandray
What the #MAMS design does is enable testing multiple drugs simultaneously, flexibility to drop unpromising ones & add new promising ones even midway during the trial. This was crucial in the #COVID__19 pandemic where the situation has been constantly evolving
Read 16 tweets
12 Sep
I’ve been watching with increasing concern at the trend of new daily diagnoses of COVID-19 in India over the past two weeks. To me, this reflects general public mood which seems to have begun to ignore the threat this virus poses. Thread
While the good news is that our death rates haven’t been as bad as some of the other countries (we might debate the accuracy of death reporting), but with a population of 1.35 billion people, the absolute numbers are still sobering. And rural India is just beginning to get hit
What I’d like to see is reliable “Excess mortality” and a P score which will quantify the true impact of the pandemic on deaths in India. We know that Mumbai had an excess mortality of 13000 deaths between Apr and Jul 2020. We don’t yet have data for India as a whole.
Read 23 tweets
24 Aug
I can't believe the @US_FDA Commissioner @SteveFDA announced that 35 out of 100 patients treated with #ConvalescentPlasma will benefit from it. This demonstrates either a lack of understanding of basic statistics (relative risk vs absolute risk) or external pressures. (1/n)
There are several problems with this - first, this is not based on randomized evidence. This is based on "data obtained from the ongoing National Expanded Access Treatment Protocol (EAP) sponsored by the Mayo Clinic". The preprint is available on medrxiv.org/content/10.110… (2/n)
In an observational study of 35,322 patients transfused with CP, 7-day mortality was 8.7% in those where CP was transfused early (3 days or less) and 11.9% in those transfused later (>3 days). 30 day mortality was 21.6% vs 26.7%. (3/n)
Read 13 tweets
16 Jul
The power of large, pragmatic randomized trials. Conducted by academic researchers using an adaptive trial design (#MAMS), and you’ve got a winner. Strong reasons why publicly funded research is so very important. Thread
The #RECOVERY trial has answered 3 important, clinically relevant questions about #COVID_19. It has shown that #Dexamethasone is beneficial in patients requiring oxygen/ ventilation & that HCQ and Lopinavir-Ritonavir are not useful.
#HCQ results are now out in preprint!
#RECOVERY randomized 1561 pts to #HCQ and 3155 to standard of care. Primary endpoint of 28-day mortality was 26.8% in the HCQ arm and 25% in the SOC arm. Lack of benefit consistent across all sub-groups. And remember, 28-day mortality in the same trial in the Dexa arm was 21.6%
Read 6 tweets
6 Jun
The retractions of papers in @TheLancet and the @NEJM have been met with outrage, anger and calls for resignation of the editors. Let's take a moment to think about this. What is a journal's and an editor's responsibility? To ensure that they publish the best science. Thread
They also need to publish the best science reliably and in a timely manner. How do they do this? They send to peer reviewers, get comments, and make a decision. They also rely heavily on authors for the veracity and integrity of the paper and their potential or real COI
Authors sign a declaration that they vouch for the data they present. Given the present circumstances in science, is it realistic to expect that editors and reviewers get the raw data of every single study that's submitted to their journal to guide their decision?
Read 6 tweets
27 Feb
I am extremely skeptical about tests like these. Screening for cancer (or any other disease) should have strong evidence to back it, failing which the test will only exploit innocent public. What do I mean by evidence to support it?
Thread
The only reliable evidence to support screening is from large randomized trials offering screening to one arm & routine care to the other, & conclusively demonstrate decreased mortality in the screened arm. Sorry, but no alternative expedient methods of "evidence" matter. Why?
Screening has the real potential for harm, by way of unnecessary tests, interventions that can cause harm, or even death, diverting scarce health resources to useless treatment & costs involved. Which is why, if there is no mortality reduction, the screening tool is merely a tool
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!